NANOG, a homeobox TF, is also a biomarker of tumor pluripotency in various cancers, such as ovarian, breast, and prostate cancers, with NANOG stability being assured through phosphorylation by ERK and cyclin-dependent kinase 1 (CDK1) [64,70]. Here, CDK1 is linked to prostate cancer.